{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:48:09Z","timestamp":1790099289450,"version":"4.0.1"},"reference-count":13,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Carboplatin hypersensitivity reactions have been reported to occur in up to 16% of patients with gynecologic cancers. Several predisposing factors have been suggested including presence of BRCA1\/2 mutation, however, contribution of these mutations to reaction development has not been extensively studied. The purpose of this study was to determine if there is an association between BRCA1\/2 mutation status and the development of carboplatin hypersensitivity reactions. Methodology: Eligible patients were women aged 18 years or older with a diagnosis of ovarian, fallopian tube, uterine, endometrial, or primary peritoneal cancer who attempted to receive at least one dose of carboplatin. The primary outcome was the effect of BRCA1\/2 status on the development of carboplatin hypersensitivity reactions with regard to: reaction frequency, timing, and severity. Secondary outcomes included identification of additional risk factors that may help identify predisposition to carboplatin hypersensitivity reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 44 patients were included in this study. Five patients (38%) in the reaction group and 4 patients (31%) in the no reaction group had a documented mutation in one or both BRCA genes (p\u2009=\u20091.00). No significant differences were found in terms of reaction severity or symptoms, and timing of reaction after dose administration. Incidence of thyroid disorder was significantly higher among patients who experienced a hypersensitivity reaction (1 (4%) vs 10 (45%); p\u2009=\u20090.004).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BRCA mutation status was not associated with an increased risk of carboplatin hypersensitivity in our patient population. Further investigation into thyroid dysfunction as a risk factor for reaction development is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220967988","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:56:57Z","timestamp":1603673817000},"page":"1704-1709","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9830-3274","authenticated-orcid":false,"given":"Melanie","family":"Rolfe","sequence":"first","affiliation":[{"name":"Lee Health, Fort Myers, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gegeckas","sequence":"additional","affiliation":[{"name":"Regional Cancer Center, Fort Myers, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Turner","sequence":"additional","affiliation":[{"name":"Lee Health, Fort Myers, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James W","family":"Orr","sequence":"additional","affiliation":[{"name":"Fl Gynecologic Oncology & Regional Cancer Care, Fort Myers, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"bibr1-1078155220967988","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (Version 2), www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf (2018, accessed 25 September 2018)."},{"key":"bibr2-1078155220967988","unstructured":"National Comprehensive Cancer Network. Uterine neoplasm (Version 2), www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf (2018, accessed 25 September 2018)."},{"key":"bibr3-1078155220967988","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70363-2"},{"key":"bibr4-1078155220967988","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153"},{"key":"bibr5-1078155220967988","doi-asserted-by":"publisher","DOI":"10.1159\/000055363"},{"key":"bibr6-1078155220967988","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.03.015"},{"key":"bibr7-1078155220967988","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00800"},{"key":"bibr8-1078155220967988","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.389"},{"key":"bibr9-1078155220967988","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.08.012"},{"key":"bibr10-1078155220967988","unstructured":"American Thyroid Association. Hashimoto\u2019s Thyroiditis (Lymphocytic Thyroiditis), https:\/\/www.thyroid.org\/hashimotos-thyroiditis\/. 2019."},{"key":"bibr11-1078155220967988","doi-asserted-by":"crossref","unstructured":"Sanjuan MA, Sagar D and Kolbeck R. Role of IgE in autoimmunity. J\n                      Allergy Clin Immunol\n                      2016; 137(6): 1651\u20131661.","DOI":"10.1016\/j.jaci.2016.04.007"},{"key":"bibr12-1078155220967988","doi-asserted-by":"crossref","unstructured":"Degirmenci PB, Kirmaz C, Oz D, et al. Allergic rhinitis and its relationship with autoimmune thyroid diseases.\n                      Am J Rhinol Allergy\n                      2015; 29(4): 257\u201361.","DOI":"10.2500\/ajra.2015.29.4189"},{"key":"bibr13-1078155220967988","doi-asserted-by":"crossref","unstructured":"Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.\n                      Met Based Drugs\n                      2010; 2010: 207084.","DOI":"10.1155\/2010\/207084"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220967988","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220967988","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220967988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:04Z","timestamp":1777688644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220967988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1177\/1078155220967988"],"URL":"https:\/\/doi.org\/10.1177\/1078155220967988","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,25]]}}}